MDR Focus Achaogen targets MDR gram-negative infections, a high-need space with potential for premium pricing and rapid clinical adoption if programs advance. This presents a sales opportunity to offer late-stage development, regulatory, and commercialization support to pharma companies expanding their anti-infective portfolios.

Strategic Partnerships Past asset sale to Cipla indicates openness to strategic collaborations or divestitures. Identify buyers or licensees seeking MDR assets or in-licensing opportunities and propose co-development, licensing, or strategic advisory services to maximize value.

Regulatory Footprint EMA Marketing Authorization Application activity for plazomicin shows capability to navigate global regulatory processes. Offer regulatory affairs, market access, and payer strategy services to firms pursuing EU or global approvals for anti-infectives.

Cost Efficient Model 2019 headcount reductions and restructuring point to a cost-conscious pivot. Position as a partner for outsourced clinical operations, regulatory affairs, and other services that reduce fixed costs for biotechnology programs.

Financial Flexibility Moderate revenue and limited funding suggest a preference for capital-efficient partnerships. Propose milestone-based licensing, upfront payments with royalties, or co-development agreements to share risks and align incentives.